β-Blocker use and diabetes symptom score: Results from the GEMINI study

Research output: Contribution to journalArticle

Janet B. Mcgill, G. L. Bakris, V. Fonseca, P. Raskin, F. H. Messerli, Robert A. Phillips, R. E. Katholi, J. T. Wright, M. Iyengar, K. M. Anderson, M. A. Lukas, M. R. Dalal, S. H. Bell

Aim: The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two β-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes. In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two β-blockers on commonly reported symptoms. Methods: The Diabetes Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of diabetes-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5). The DSC assessed symptoms in eight domains: psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycaemia and hypoglycaemia. Results: Comparison ofthe mean change in self-reported diabetes-related symptoms indicated a significant treatment difference favouring carvedilol over metoprolol tartrate in overall symptom score (-0.08; 95% CI -0.15, -0.01; p = 0.02) and in the domains for hypoglycaemia symptoms (-0.12; 95% CI -0.23, -0.02; p = 0.02) and hyperglycaemia symptoms (-0.16; 95% CI -0.27, -0.05; p = 0.005). Carvedilol resulted in fewer perceived diabetes-related symptoms in patients with diabetes and hypertension. Conclusion: Carvedilol resulted in a lower perceived burden of diabetes-related symptoms in patients with type 2 diabetes and hypertension. The addition of a well-tolerated β-blocker to RAS blockade may improve hypertension treatment and quality of life in patients with diabetes.

Original languageEnglish (US)
Pages (from-to)408-417
Number of pages10
JournalDiabetes, Obesity and Metabolism
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2007

PMID: 17391169

Altmetrics

Cite this

Standard

β-Blocker use and diabetes symptom score : Results from the GEMINI study. / Mcgill, Janet B.; Bakris, G. L.; Fonseca, V.; Raskin, P.; Messerli, F. H.; Phillips, Robert A.; Katholi, R. E.; Wright, J. T.; Iyengar, M.; Anderson, K. M.; Lukas, M. A.; Dalal, M. R.; Bell, S. H.

In: Diabetes, Obesity and Metabolism, Vol. 9, No. 3, 01.01.2007, p. 408-417.

Research output: Contribution to journalArticle

Harvard

Mcgill, JB, Bakris, GL, Fonseca, V, Raskin, P, Messerli, FH, Phillips, RA, Katholi, RE, Wright, JT, Iyengar, M, Anderson, KM, Lukas, MA, Dalal, MR & Bell, SH 2007, 'β-Blocker use and diabetes symptom score: Results from the GEMINI study' Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 408-417. https://doi.org/10.1111/j.1463-1326.2006.00693.x

APA

Mcgill, J. B., Bakris, G. L., Fonseca, V., Raskin, P., Messerli, F. H., Phillips, R. A., ... Bell, S. H. (2007). β-Blocker use and diabetes symptom score: Results from the GEMINI study. Diabetes, Obesity and Metabolism, 9(3), 408-417. https://doi.org/10.1111/j.1463-1326.2006.00693.x

Vancouver

Mcgill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA et al. β-Blocker use and diabetes symptom score: Results from the GEMINI study. Diabetes, Obesity and Metabolism. 2007 Jan 1;9(3):408-417. https://doi.org/10.1111/j.1463-1326.2006.00693.x

Author

Mcgill, Janet B. ; Bakris, G. L. ; Fonseca, V. ; Raskin, P. ; Messerli, F. H. ; Phillips, Robert A. ; Katholi, R. E. ; Wright, J. T. ; Iyengar, M. ; Anderson, K. M. ; Lukas, M. A. ; Dalal, M. R. ; Bell, S. H. / β-Blocker use and diabetes symptom score : Results from the GEMINI study. In: Diabetes, Obesity and Metabolism. 2007 ; Vol. 9, No. 3. pp. 408-417.

BibTeX

@article{d85d34380d1f4d11b1655391b3c83fb7,
title = "β-Blocker use and diabetes symptom score: Results from the GEMINI study",
abstract = "Aim: The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two β-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes. In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two β-blockers on commonly reported symptoms. Methods: The Diabetes Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of diabetes-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5). The DSC assessed symptoms in eight domains: psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycaemia and hypoglycaemia. Results: Comparison ofthe mean change in self-reported diabetes-related symptoms indicated a significant treatment difference favouring carvedilol over metoprolol tartrate in overall symptom score (-0.08; 95{\%} CI -0.15, -0.01; p = 0.02) and in the domains for hypoglycaemia symptoms (-0.12; 95{\%} CI -0.23, -0.02; p = 0.02) and hyperglycaemia symptoms (-0.16; 95{\%} CI -0.27, -0.05; p = 0.005). Carvedilol resulted in fewer perceived diabetes-related symptoms in patients with diabetes and hypertension. Conclusion: Carvedilol resulted in a lower perceived burden of diabetes-related symptoms in patients with type 2 diabetes and hypertension. The addition of a well-tolerated β-blocker to RAS blockade may improve hypertension treatment and quality of life in patients with diabetes.",
keywords = "Carvedilol, Diabetes, Diabetes Symptom Checklist, Metoprolol tartrate, Quality of life, Symptom score",
author = "Mcgill, {Janet B.} and Bakris, {G. L.} and V. Fonseca and P. Raskin and Messerli, {F. H.} and Phillips, {Robert A.} and Katholi, {R. E.} and Wright, {J. T.} and M. Iyengar and Anderson, {K. M.} and Lukas, {M. A.} and Dalal, {M. R.} and Bell, {S. H.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1463-1326.2006.00693.x",
language = "English (US)",
volume = "9",
pages = "408--417",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - β-Blocker use and diabetes symptom score

T2 - Diabetes, Obesity and Metabolism

AU - Mcgill, Janet B.

AU - Bakris, G. L.

AU - Fonseca, V.

AU - Raskin, P.

AU - Messerli, F. H.

AU - Phillips, Robert A.

AU - Katholi, R. E.

AU - Wright, J. T.

AU - Iyengar, M.

AU - Anderson, K. M.

AU - Lukas, M. A.

AU - Dalal, M. R.

AU - Bell, S. H.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Aim: The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two β-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes. In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two β-blockers on commonly reported symptoms. Methods: The Diabetes Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of diabetes-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5). The DSC assessed symptoms in eight domains: psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycaemia and hypoglycaemia. Results: Comparison ofthe mean change in self-reported diabetes-related symptoms indicated a significant treatment difference favouring carvedilol over metoprolol tartrate in overall symptom score (-0.08; 95% CI -0.15, -0.01; p = 0.02) and in the domains for hypoglycaemia symptoms (-0.12; 95% CI -0.23, -0.02; p = 0.02) and hyperglycaemia symptoms (-0.16; 95% CI -0.27, -0.05; p = 0.005). Carvedilol resulted in fewer perceived diabetes-related symptoms in patients with diabetes and hypertension. Conclusion: Carvedilol resulted in a lower perceived burden of diabetes-related symptoms in patients with type 2 diabetes and hypertension. The addition of a well-tolerated β-blocker to RAS blockade may improve hypertension treatment and quality of life in patients with diabetes.

AB - Aim: The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two β-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes. In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two β-blockers on commonly reported symptoms. Methods: The Diabetes Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of diabetes-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5). The DSC assessed symptoms in eight domains: psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycaemia and hypoglycaemia. Results: Comparison ofthe mean change in self-reported diabetes-related symptoms indicated a significant treatment difference favouring carvedilol over metoprolol tartrate in overall symptom score (-0.08; 95% CI -0.15, -0.01; p = 0.02) and in the domains for hypoglycaemia symptoms (-0.12; 95% CI -0.23, -0.02; p = 0.02) and hyperglycaemia symptoms (-0.16; 95% CI -0.27, -0.05; p = 0.005). Carvedilol resulted in fewer perceived diabetes-related symptoms in patients with diabetes and hypertension. Conclusion: Carvedilol resulted in a lower perceived burden of diabetes-related symptoms in patients with type 2 diabetes and hypertension. The addition of a well-tolerated β-blocker to RAS blockade may improve hypertension treatment and quality of life in patients with diabetes.

KW - Carvedilol

KW - Diabetes

KW - Diabetes Symptom Checklist

KW - Metoprolol tartrate

KW - Quality of life

KW - Symptom score

UR - http://www.scopus.com/inward/record.url?scp=33947625081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947625081&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2006.00693.x

DO - 10.1111/j.1463-1326.2006.00693.x

M3 - Article

VL - 9

SP - 408

EP - 417

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -

ID: 16853030